Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42

Raymond James analyst Thomas Deal has initiated coverage on Odyssey Therapeutics (NASDAQ: ODTX) with an Outperform rating. The firm has set a price target of $42 for the company's stock.